Emerging integrase resistance in an international perinatal virtual clinic
Although uncommon, INSTI resistance is emerging, mainly in highly treatment experienced CAWHIV from LMIC, highlighting the global need for access to boosted protease inhibitors and novel classes, including formulations for children less than 35 kg.
Authors
- Anna Turkova (ORCID: https://orcid.org/0000-0002-7008-4145)
- Jessica Glenn
- Angela Bailey (ORCID: https://orcid.org/0000-0002-9817-0715)
- Alasdair Bamford (ORCID: https://orcid.org/0000-0003-4764-229X)
- Julia Kenny (ORCID: https://orcid.org/0000-0002-9821-794X)
- Tiago Milheiro Silva (ORCID: https://orcid.org/0000-0003-1170-5674)
- Steven Welch (ORCID: https://orcid.org/0000-0002-6923-3502)
- Caroline Foster (ORCID: https://orcid.org/0000-0001-8278-8564)
- Leon Levin (ORCID: https://orcid.org/0000-0002-2377-6480)
- Ayolola Eni‐Olotu (ORCID: https://orcid.org/0000-0002-9187-9692)
- Neil Tickner
- Hermione Lyall (ORCID: https://orcid.org/0000-0001-6114-7215)
- Katherine Simon (ORCID: https://orcid.org/0000-0001-9232-2653)
- Nicola Mackie
Institutions
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Imperial College Healthcare NHS Trust (GB)
- Baylor College of Medicine (US)
- Great Ormond Street Hospital for Children NHS Foundation Trust (GB)
- Buckinghamshire Healthcare NHS Trust (GB)
- Imperial Valley College (US)
- MRC Clinical Trials Unit at UCL (GB)
- Hospital de Dona Estefânia (PT)
- Evelina London Children's Healthcare (GB)
- Right to Care (ZA)
Publication Details
- Journal
- AIDS
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1097/qad.0000000000004048
- Citations
- 4
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.56